3 recruiting, 1 completed, 1 not yet recruiting, 1 unknown. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Recruiting 3, Completed 1, Not yet recruiting 1, Unknown 1 |
Follow Chronic Lymphocytic Leukemia: new trials by email Literature Review of Chronic Lymphocytic Leukemia trials Research Report on Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Pirtobrutinib, Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 4 | Recruiting | Eli Lilly and Company | 150 | 2026-03-09 | 2026-11-04 |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 279 | 2025-05-20 | 2026-03-02 |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 787 | 2025-05-20 | 2026-03-02 |
| Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens Venetoclax - Chronic Lymphocytic Leukemia | Phase 4 | Not yet recruiting | Paolo Ghia | 30 | 2023-11-01 | 2023-10-03 |
| Antiviral Treatment of Chronic Lymphocytic Leukemia Valganciclovir - Chronic Lymphocytic Leukemia | Phase 4 | Completed | Medical University of Vienna | 20 | 2010-12-01 | 2015-07-21 |
| Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Nipent, Cytoxan, Rituxan - Chronic Lymphocytic Leukemia | Phase 4 | Unknown | East Valley Hematology and Oncology Medical Group | 180 | 2003-01-01 | 2005-08-18 |
Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Non-Hodgkin (2) · Leukemia (1) · Neoplasms (1)
Chronic Disease (6) · Disease Attributes (6) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Leukemia, B-Cell (6) · Leukemia, Lymphoid (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Neoplasms by Histologic Type (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Leukemia (5) · Neoplasms (5)
pirtobrutinib (3) · Biopsy, Needle (1) · Cyclophosphamide (1) · Pentostatin (1) · Rituximab (1) · Valganciclovir (1) · idelalisib (1) · venetoclax (1)
Eli Lilly and Company (3) · East Valley Hematology and Oncology Medical Group (1) · Medical University of Vienna (1) · Paolo Ghia (1)
United States (4) · Australia (3) · France (3) · Italy (3) · Japan (3) · Poland (3) · United Kingdom (3) · Austria (2) · South Korea (2) · Belgium (1) · Canada (1) · China (1) · Croatia (1) · Czechia (1) · Hungary (1)
Christoph Steininger, MD (1) · Raul Mena, MD (1)